SXTP Stock Forecast & Price Target

60 Degrees is supported by a clearer clinical catalyst in tafenoquine, where all three enrolled patients in the March babesiosis update were cured after completing the regimen in the relapsing babesiosis study in immunosuppressed patients, reinforcing the therapeutic promise of its infectious-disease pipeline. The ARAKODA franchise also shows commercial traction in 2026 through the February GoodRx launch and the April Runway Health partnership, while the Australian Chestnut extract option adds a lower-risk, non-Rx opportunity that could broaden monetization. Although Q1 ATM sales generated about $3.4 million net and cash finished at $3.3 million, the roughly $8 million annual burn rate implies ongoing dilution risk, but the pipeline momentum and product-expansion strategy support a constructive outlook.

60 Degrees is facing a fundamentally weak outlook because Q1 FY26 showed a wider-than-expected net loss of $2.2 million on just $0.2 million of sales, alongside EPS of $(1.28) versus the estimated $(0.99). Revenue softness was driven by lower ARAKODA sell-through, higher returns from expiring product lots, and 19% year-over-year unit decline to 1,276 boxes, while operating expenses still rose to $2.2 million and no forward guidance was provided. The deterioration in FY26 and FY27 estimates, plus recent ATM dilution and uncertainty around funding, clinical progress, and commercial traction, underscores elevated execution and financing risk.